查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827367

基因组学市场（按产品类型、应用、最终用户和技术）—2025-2032 年全球预测

Genomics Market by Product Type, Application, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年基因组学市场规模将成长至 1,122.6 亿美元，复合年增长率为 10.03%。

主要市场统计数据
基准年2024年 522.2亿美元
预计2025年 571.5亿美元
预测年份：2032年 1122.6亿美元
复合年增长率（%） 10.03%

为研究、临床和商业相关人员制定当前基因组学趋势、技术考量和关键决策的策略方向

基因组学领域持续快速发展，技术创新、跨部门合作以及不断变化的监管环境重塑了研究机构、医疗保健提供者和商业公司的策略重点。本简介概述了高阶主管、研发主管和采购团队在评估技术采用、合作机会和资本配置时必须考虑的关键驱动因素。此外，本简介也将该主题置于更广泛的背景下进行探讨，包括转化科学、供应链韧性以及对精准治疗和诊断方法日益增长的需求。

新的定序平台、改进的PCR方法以及微阵列设计的创新正在释放新的实验能力，同时也改变了供应商的竞争和服务模式。同时，从农业到个人化医疗等各种应用领域，组织必须管理的端点数量和资料类型也不断增加。因此，技术投资或外包的决策不仅取决于仪器性能和试剂质量，还取决于与生物资讯流程的整合、试样处理通量的可扩展性以及耗材的长期可用性。

在此背景下，相关人员必须权衡短期营运需求与长期策略目标。本报告的第一部分探讨了许多关键问题，例如，面对多样化的用例，如何确定平台选择的优先级，如何降低供应和监管风险，以及如何将技术优势转化为可衡量的临床和商业性价值。本书旨在帮助读者掌握对研究、临床和商业成果产生最大影响的槓桿。

技术突破、商业模式演变以及监管预期的提高如何改变基因组学领域的竞争动态和业务重点

成熟的技术、不断变化的经营模式以及新兴的政策动态相互作用，正在改变基因组学格局，并引发需要策略调整的重大变革。高通量定序和单细胞技术的进步正在降低产生复杂数据集的门槛，从而促进从孤立实验向整合多组体学项目的转变。这种转变有利于那些能够将分析深度与强大的资料管理和解读框架结合的组织，从而不仅透过原始通量，更透过切实可行的洞察脱颖而出。

同时，某些硬体组件的商品化以及以试剂为中心的经营模式的兴起正在改变供应商的经济状况，并加速规模至上的细分市场的整合。服务供应商正在扩展其端到端解决方案，包括样本物流、定序、资料处理和法规支持，以吸引那些追求简单性和品质保证的客户。同时，人们对精密农业和感染疾病监测的兴趣日益浓厚，这正在扩大最终用户的覆盖范围，并催生出能够快速部署基因组学能力的邻近市场。

最后，伦理和监管部门对资料隐私、跨国样本流动和临床检验的关注，已将管治提升到竞争层面。积极整合合规性、透明的资料管理和检验的工作流程的组织将占据有利地位，从而获得长期价值。这些变革性转变并非孤立运作，而是动态互动的，这意味着技术选择、商业性伙伴关係和合规策略必须协调一致，才能有效应对新的情况。

评估2025年关税如何重塑基因组学业务的筹资策略、供应链弹性计画和供应商风险分配

关税和贸易限制等措施的实施可能会对基因组学生态系统产生多层次的影响，影响供应商关係、采购决策以及实验室运作的成本结构。 2025年的关税促使采购团队重新评估其供应商组合，实现采购多元化，并加快对替代供应商的资格审查，以确保关键设备和耗材的持续供应。这项转变导致企业更加重视拥有弹性製造足迹和透明关税减免策略的供应商。

在实践中，各机构已做出应对，将部分采购转向国产零件，并增加常用试剂和耗材的战略存量基准。与服务提供者和设备供应商的合约条款已重新协商，以考虑更长的前置作业时间并分摊跨境物流相关风险。此外，关税带来的成本压力影响了资本支出计划，一些买家推迟了非必要的设备升级，同时优先采购正在进行的研究和临床工作流程所需的耗材。

从策略角度来看，关税凸显了供应链情报和情境规划的重要性。相关人员正在投资更深入的供应商审核、双重采购策略，并与製造商建立更紧密的合作，以绘製生产能力图并识别瓶颈。从中期来看，这些调整可能会鼓励本地化製造和长期合约安排的扩张，从而即使在贸易政策波动的情况下也能提供可见性和可预测性。因此，虽然关税带来了直接挑战，但它们也加速了整个基因组学领域采购惯例和供应链设计的结构性变革。

全面的細項分析涵盖产品、应用、最终用户和技术维度，以指导有针对性的研发、商业化和服务策略

了解市场区隔对于制定基因组学领域的产品开发、商业策略和服务交付模式至关重要。市场分析涵盖产品类型，涵盖微阵列、PCR、试剂和耗材、定序服务和定序系统。微阵列分为基因表现阵列和SNP基因型鉴定阵列，PCR分为数位PCR和qPCR，试剂和耗材包括酵素和预混液、文库製备试剂套件以及探针和引物，定序服务包括新一代定序和桑格定序服务，定序系统包括NGS平台和桑格定序仪。这种以产品为中心的观点突显了技术创新的发生地点，以及传统平台的生命週期压力可能促使其进行再投资或迁移的领域。

从应用角度来看，市场涵盖农业、诊断、药物发现和市场开发以及个人化医疗。由于样本类型和分析要求不同，农业领域分为动物基因组学和作物基因组学。诊断领域分为癌症基因组学、基因检测和传染病检查，每种检测都需要不同的检验途径和临床工作流程。药物发现和开发专注于生物标记的发现和标靶识别，是一项依赖高通量、可重复输出的活动。个人化医疗包括伴随诊断和精准医疗，其中临床整合和监管协调至关重要。

考虑最终用户揭示了各种组织的需求和购买行为，从学术和政府机构到商业研究组织、医院和诊所、製药公司和生物技术公司。这些最终用户在采购复杂程度、吞吐量要求和营运风险接受度能力方面各不相同。透过技术视角评估市场突显了阵列技术、DNA定序、PCR技术和RNA定序的影响。阵列技术进一步分为微阵列、基因表现阵列和SNP基因型鉴定阵列；DNA定序分为次世代定序和桑格定序；PCR技术分为数位PCR和qPCR；RNA定序分为批量RNA定序和定序细胞RNA定序。 PCR技术也分为数位PCR和qPCR，RNA定序分为批量RNA定序和单细胞RNA定序。这些细分框架提供了一个全面的地图，用于将研发蓝图、销售策略和服务设计与不同客户群的细微需求相结合。

区域情报观点将美洲、欧洲、中东和非洲地区以及亚太地区的采用驱动因素、监管变化和伙伴关係机会连结起来

区域动态在决定整个基因组学生态系统的采用模式、监管途径和伙伴关係方面发挥着至关重要的作用。美洲拥有大型学术中心、综合医疗保健系统和蓬勃发展的生物技术产业，这催生了对先进定序和精准诊断的需求，同时也促进了商业开发商和临床实施者之间的密切合作。这种环境有利于将研究创新快速转化为临床检验试验和商业部署。

欧洲、中东和非洲 (EMEA) 市场的特点是法律规范和医疗保健服务模式的多样性，这对标准化和跨境合作产生了影响。该地区拥有强大的专业研究和转化倡议能力，为利用专业知识和共用基础设施的联盟计划提供了独特的机会。合规性和国家报销政策通常决定临床应用的速度和轨迹。

在国内製造业投资、不断增长的临床定序项目以及日益增多的诊断实验室的推动下，亚太地区在学术研究和商业应用领域的应用正在快速发展。公共卫生计划和农业基因组学计画等区域市场动态正在拓展基因组学技术的潜在应用。不同地区在报销、监管透明度和製造能力方面的差异持续影响策略进入方式和伙伴关係模式。

以平台整合、服务扩展和策略伙伴关係关係为中心的供应商策略如何重新定义竞争优势和客户维繫

主要企业在平台整合、服务多元化和策略伙伴关係方面的投资正在塑造其竞争轨迹，从而获取超越单一产品销售的价值。将仪器创新与强大的试剂组合和扩充性服务相结合的公司，能够提供满足端到端客户需求的整合解决方案。此外，在软体、数据分析和云端解读服务方面的投资正在创造新的收益来源，并透过持续的服务模式增强客户留存率。

对于寻求快速拓展潜在市场且避免重复资本投入的公司而言，策略联盟和OEM合作关係日益普遍。此类联盟可以加速新型检测方法的上市时间，共用临床检验风险，并提供互补的能力，进而提升整体解决方案的价值。同时，中端市场公司和专业创新者继续提供差异化技术，尤其是在单细胞分析和新型文库製备化学等利基应用领域。

竞争定位也取决于供应链和品质系统的卓越运作。能够展现透明生产实践、强大品管和快速响应的技术支援的开发人员将赢得关键终端用户的信任，例如临床实验室和药品开发人员。最终，最成功的公司将是那些能够平衡技术差异化、可证明的客户成果和可扩展商业模式的公司。

高阶主管可以采取切实有效的行动来增强供应链弹性，实现平台互通性，并提供以结果为导向的服务来推动采用

为了因应不断变化的基因组学环境，产业领导者必须采取一系列切实可行的措施，重点关注供应链弹性、平台互通性和价值主导的客户参与。首先，企业应优先考虑关键耗材的双重采购和本地库存策略，以减轻贸易政策波动和物流中断的影响。与关键供应商签订多年期合约并投资于供应商可视性工具，将降低风险并提供营运可预测性。

其次，产品和服务策略应强调互通性和资料可携性。设计易于与常用实验室资讯系统和生物资讯流程整合的仪器和软体，可以降低采用门槛，并增强商业性关係的黏性。同样重要的是注重以结果为导向的服务。将分析能力与解读报告以及临床或农业见解相结合，可以在竞争激烈的市场中脱颖而出。

最后，领导者应投资于监管准备和透明的资料管治实践。积极与监管机构合作，采用最佳实践验证通讯协定，并展示强大的资料管理能力，可以加速临床应用并建立相关人员的信任。在策略伙伴关係、共同开发契约和地理扩张方面的互补性投资，可以使组织在满足本地市场需求的同时，负责任地扩大规模。这些综合行动使行业领导者能够在短期市场波动的情况下获得长期价值。

采用严格的多源调查方法，结合主要相关人员访谈、专家文献综述和分析框架检验趋势和策略意义

本研究采用了多层面的方法，结合了主要相关人员访谈、技术文献综述以及系统性的产品和研发分析，以确保观点的全面性和平衡性。主要研究包括与研发负责人、临床实验室主任、采购专家以及仪器和试剂供应商的商业负责人的对话。这些对话旨在深入了解营运挑战、应用驱动因素以及对不断变化的政策和供应链格局的策略反应。

我们的二次研究包括查阅同行评审日誌、会议论文集、专利申请和公开监管文件，以检验技术趋势并追踪关键技术的演变。此外，我们还整合了产品规格目录、供应商揭露和公开案例研究，以绘製功能差距、整合能力和部署环境。调查方法着重于跨资讯来源三角测量，以减少偏见并协调对技术成熟度和临床准备度的不同观点。

此分析架构涵盖细分市场映射、供应链风险情境规划，以及基于定价、服务范围和客户支援安排的商业模式评估。在整个过程中，我们运用品质保证流程来核实事实准确性，并确保结论得到多项独立输入的支援。最终形成了一项严谨的、基于证据的评估，旨在为策略规划和营运决策提供参考。

结论性综合评估强调适应性、技术整合和管治是不断发展的基因组学生态系统持续成功的关键因素

总而言之，我们重申，基因组学正处于曲折点，技术能力、商业性创新和监管管理在此交汇，决定未来的赢家和落后者。能够将投资整合到可互通平台、弹性供应链和成果主导服务中的组织，将创造持久的竞争优势。此外，积极应对监管和数据管治问题，将加速实验室进步转化为临床和商业性效益。

展望未来，将复杂资料流转化为可操作决策（例如开发治疗方法、部署诊断方法和改进农业）的能力，将使高绩效组织脱颖而出。策略伙伴关係、灵活的经营模式以及对客户成果的持续关注，将使公司能够抓住新机会，同时降低营运风险。关键讯息是，适应性、技术力和可靠性是快速变化的基因组学生态系统中的关键要素。

最后，本分析为领导者确定投资优先顺序、制定产品蓝图和完善商业性方法提供了结构性基础。透过专注于那些对采用和价值实现影响最大的槓桿，组织能够应对不确定性，并在研究、临床护理和更广泛的基因组学应用领域产生永续的影响。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 快速采用奈米孔长读定序进行临床诊断中的全面结构变异分析
  • 将多组体学数据与人工智慧演算法结合，加速标靶药物研发流程
  • 随着全球大流行防范工作的进展，利用可携式定序设备扩大即时病原体监测
  • 直接面向消费者的基因健康检测的扩展及其相关的隐私和监管挑战
  • 用于早期癌症检测和精准肿瘤学决策的新兴表观遗传生物标记组
  • 主要国际市场对 CRISPR 基因编辑疗法的监管协调努力
  • 引进云端原生基因组资料平台，简化研究协作与资料共用
  • 利用单细胞多体学分析揭示复杂疾病中的细胞异质性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 基因组学市场（依产品类型）

  • 微阵列
    • 基因表现阵列
    • SNP基因型鉴定阵列
  • PCR
    • 数位PCR
    • 定量PCR
  • 试剂和耗材
    • 酵素和预混液
    • 文库製备试剂套件
    • 探针和引子
  • 定序服务
    • NGS服务
    • 桑格定序服务
  • 定序系统
    • NGS平台
    • 桑格定序仪

第九章 基因组学市场（按应用）

  • 农业
    • 动物基因体学
    • 作物基因组学
  • 诊断
    • 癌症基因体学
    • 基因检测
    • 传染病检查
  • 药物研发
    • 生物标记发现
    • 目标识别
  • 个人化医疗
    • 伴随诊断
    • 精准治疗

第 10 章 基因组学市场（按最终用户划分）

  • 学术和政府机构
  • 商业研究机构
  • 医院和诊所
  • 製药和生物技术公司

第 11 章：基因组学市场（按技术）

  • 阵列技术
    • 微阵列基因表现
    • SNP基因型鉴定阵列
  • DNA序列分析
    • 次世代定序
    • 桑格定序
  • PCR技术
    • 数位PCR
    • 定量PCR
  • RNA定序
    • 批量RNA定序
    • 单细胞RNA定序

第十二章 基因组学市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章：基因组学市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按国家/地区分類的基因组学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • QIAGEN NV
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • PerkinElmer, Inc.
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Pacific Biosciences of California, Inc.
Product Code: MRR-434CCDA04CD1

The Genomics Market is projected to grow by USD 112.26 billion at a CAGR of 10.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 52.22 billion
Estimated Year [2025] USD 57.15 billion
Forecast Year [2032] USD 112.26 billion
CAGR (%) 10.03%

A strategic orientation that frames current genomics trends, technology considerations, and critical decisions for research, clinical, and commercial stakeholders

The landscape of genomics continues to evolve rapidly as technological innovation, cross-sector collaboration, and shifting regulatory expectations reshape strategic priorities for research institutions, healthcare providers, and commercial enterprises. This introduction synthesizes the principal drivers that executives, R&D leaders, and procurement teams must consider when evaluating technology adoption, partnership opportunities, and capital allocation. It situates the topic within the broader context of translational science, supply chain resilience, and the intensifying demand for precision approaches across therapeutics and diagnostics.

Emerging sequencing platforms, refinements in PCR modalities, and innovations in microarray design are unlocking new experimental capabilities while simultaneously altering vendor competition and service models. At the same time, applications spanning agriculture to personalized medicine are increasing the number of endpoints and data types that organizations must manage. Consequently, decisions about technology investments and outsourcing relationships are informed not only by instrument performance and reagent quality, but also by integration with bioinformatic pipelines, scalability of sample throughput, and long-term consumables availability.

Against this backdrop, stakeholders must weigh near-term operational needs against longer-term strategic objectives. This report's opening section frames the critical questions: how to prioritize platform selection in the face of heterogeneous use cases, how to mitigate supply and regulatory risks, and how to translate incremental technical advantages into measurable clinical or commercial value. The objective is to orient readers to the levers that will most significantly influence outcomes across research, clinical, and commercial settings.

How converging technology breakthroughs, evolving commercial models, and rising regulatory expectations are reshaping competitive dynamics and operational priorities in genomics

The genomics landscape is being transformed by an interplay of technological maturation, shifting business models, and emergent policy dynamics, producing structural shifts that require recalibrated strategies. Advances in high-throughput sequencing and single-cell capabilities have reduced barriers to generating complex datasets, which in turn is catalyzing a transition from siloed experiments to integrative multi-omic programs. This shift favors organizations that can combine analytical depth with robust data management and interpretation frameworks, thereby creating differentiation through actionable insights rather than raw throughput alone.

Concurrently, the commoditization of certain hardware components and the rise of reagent-focused business models are altering vendor economics and accelerating consolidation in segments where scale matters most. Service providers are expanding offerings to include end-to-end solutions that encompass sample logistics, sequencing, data processing, and regulatory support, thereby appealing to customers seeking simplicity and guaranteed quality. Meanwhile, increased interest in precision agriculture and infectious disease surveillance has broadened the range of end users and created adjacent markets where genomics capabilities can be deployed rapidly.

Finally, ethical and regulatory attention to data privacy, cross-border sample movement, and clinical validation is elevating governance as a competitive dimension. Organizations that proactively integrate compliance, transparent data stewardship, and validated workflows will be better positioned to capture long-term value. These transformative shifts are not isolated; they interact dynamically, meaning that technology choices, commercial partnerships, and compliance strategies must be aligned to navigate the new landscape effectively.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resilience planning, and vendor risk allocation within genomics operations

The implementation of measures such as tariffs and trade restrictions can generate multi-layered effects on the genomics ecosystem, influencing supplier relationships, sourcing decisions, and cost structures for laboratory operations. Tariffs introduced in 2025 have had the effect of prompting procurement teams to reassess vendor portfolios, diversify sourcing, and accelerate qualification of alternative suppliers to ensure continuity of supply for critical instruments and consumables. This reorientation has placed a premium on suppliers with resilient manufacturing footprints and transparent tariff mitigation strategies.

In practice, organizations have responded by shifting some procurement toward domestically manufactured components or by increasing strategic inventory levels for high-use reagents and consumables. Contractual terms with service providers and instrument vendors have been renegotiated to account for extended lead times and to allocate risk related to cross-border logistics. Additionally, tariff-driven cost pressures have influenced capital expenditure planning, with some purchasers delaying non-essential instrument upgrades while prioritizing consumable availability for ongoing research and clinical workflows.

From a strategic perspective, the tariffs have underscored the importance of supply chain intelligence and scenario planning. Stakeholders are investing in deeper supplier audits, dual-sourcing strategies, and closer collaboration with manufacturers to map production capacity and identify chokepoints. In the medium term, these adaptations could encourage localized manufacturing expansion and longer-term contractual arrangements that provide visibility and predictability despite trade policy volatility. Thus, while tariffs create immediate challenges, they also accelerate structural changes in procurement practices and supply chain design across the genomics sector.

Comprehensive segmentation analysis that maps product, application, end-user, and technology dimensions to guide targeted R&D, commercialization, and service strategies

Understanding market segments is essential to shaping product development, commercial strategy, and service delivery models across the genomics domain. When the market is examined by product type, the analysis spans microarrays, PCR, reagents and consumables, sequencing services, and sequencing systems; the microarrays category further differentiates into gene expression arrays and SNP genotyping arrays, while PCR divides into digital PCR and qPCR; reagents and consumables encompass enzymes and master mixes, library preparation kits, and probes and primers; sequencing services include next-generation sequencing services and Sanger sequencing services; and sequencing systems distinguish between NGS platforms and Sanger sequencers. This product-centric view highlights where innovation is occurring and where lifecycle pressures on legacy platforms may prompt reinvestment or migration.

From an application perspective, the market covers agriculture, diagnostics, drug discovery and development, and personalized medicine. Within agriculture, the focus splits into animal genomics and crop genomics, reflecting differing sample types and analytical requirements. Diagnostics breaks down into cancer genomics, genetic testing, and infectious disease testing, each demanding distinct validation pathways and clinical workflows. Drug discovery and development emphasizes biomarker discovery and target identification, activities that rely on high-throughput, reproducible output. Personalized medicine includes companion diagnostics and precision therapeutics, areas where clinical integration and regulatory alignment are paramount.

Considering end users reveals a spectrum of organizational needs and purchasing behaviors, from academic and government institutes to commercial research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies. These end users vary in procurement sophistication, throughput demands, and tolerance for operational risk. Evaluating the market through the lens of technology highlights the influence of array technology, DNA sequencing, PCR technology, and RNA sequencing. Array technology further divides into microarray gene expression and SNP genotyping arrays; DNA sequencing separates into next-generation sequencing and Sanger sequencing; PCR technology differentiates between digital PCR and qPCR; and RNA sequencing distinguishes bulk RNA sequencing from single-cell RNA sequencing. Together, these segmentation frameworks provide a comprehensive map to align R&D roadmaps, sales strategies, and service design with the nuanced needs of diverse customer cohorts.

A regional intelligence perspective that connects adoption drivers, regulatory diversity, and partnership opportunities across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics play a decisive role in determining adoption patterns, regulatory pathways, and partnership opportunities across the genomics ecosystem. In the Americas, a concentration of large academic centers, integrated healthcare systems, and an active biotechnology sector creates demand for advanced sequencing and precision diagnostics, while fostering close collaboration between commercial developers and clinical implementers. This environment encourages rapid translation of research innovations into clinical validation studies and commercial deployments.

In Europe, Middle East & Africa, the market is characterized by diversity in regulatory frameworks and healthcare delivery models, which in turn affects standardization and cross-border collaboration. The region exhibits strong capabilities in specialized research and translational initiatives, and offers unique opportunities for consortium-based projects that leverage pooled expertise and shared infrastructure. Compliance considerations and national-level reimbursement policies often shape the pace and pathway for clinical adoption.

The Asia-Pacific region demonstrates fast-paced adoption in both academic research and commercial applications, driven by investments in domestic manufacturing, growing clinical sequencing programs, and a rising base of diagnostic laboratories. Local market dynamics, including public health initiatives and agricultural genomics programs, are expanding the addressable applications for genomic technologies. Across regions, variability in reimbursement, regulatory clarity, and manufacturing capacity will continue to influence strategic entry approaches and partnership models, making regional intelligence a critical input for global planning and local execution.

How vendor strategies centered on platform integration, service expansion, and strategic partnerships are redefining competitive advantage and customer retention

Company-level behavior is shaping competitive trajectories, with leading organizations investing in platform integration, service diversification, and strategic partnerships to capture value beyond single-product sales. Firms that combine instrument innovation with robust reagent portfolios and scalable service offerings are better positioned to deliver integrated solutions that meet end-to-end customer needs. Moreover, investments in software, data analytics, and cloud-enabled interpretive services are creating new revenue streams and strengthening customer lock-in through recurring service models.

Strategic alliances and OEM relationships are increasingly common as companies seek to expand addressable markets quickly without duplicating capital expenditures. These collaborations can accelerate time to market for novel assays, enable shared risk for clinical validation, and provide complementary capabilities that enhance total solution value. Meanwhile, mid-sized players and specialized innovators continue to contribute differentiated technologies, particularly in niche applications such as single-cell analytics or novel library preparation chemistries.

Competitive positioning also hinges on operational excellence in supply chain and quality systems. Companies that demonstrate transparent manufacturing practices, robust quality management, and responsive technical support capture trust among high-stakes end users such as clinical laboratories and pharmaceutical developers. Ultimately, the most successful companies will be those that balance technological differentiation with demonstrable customer outcomes and scalable commercial models.

Practical, high-impact actions for executives to enhance supply chain resilience, enable platform interoperability, and deliver outcome-focused services that drive adoption

Industry leaders must adopt a set of actionable responses to navigate the evolving genomics environment, focusing on supply chain resilience, platform interoperability, and value-driven customer engagement. First, organizations should prioritize dual-sourcing and localized inventory strategies for critical consumables to mitigate the effects of trade policy volatility and logistics disruptions. Establishing multi-year agreements with key suppliers and investing in supplier visibility tools will reduce risk and provide operational predictability.

Second, product and services strategies should emphasize interoperability and data portability. Designing instruments and software that facilitate integration with common laboratory information systems and bioinformatics pipelines will lower barriers to adoption and increase the stickiness of commercial relationships. Equally important is an emphasis on outcome-oriented services-packaging analytical capabilities with interpretive reporting and clinical or agronomic insights will differentiate offerings in a crowded marketplace.

Finally, leaders should invest in regulatory readiness and transparent data governance practices. Proactively engaging with regulatory authorities, adopting best-practice validation protocols, and demonstrating strong data stewardship will accelerate clinical adoption and build stakeholder trust. Complementary investments in strategic partnerships, co-development agreements, and targeted regional expansion will ensure that organizations can scale responsibly while responding to localized market needs. These actions, taken together, will position industry leaders to capture long-term value despite short-term market turbulence.

A rigorous, multi-source research methodology combining primary stakeholder interviews, technical literature review, and analytical frameworks to validate trends and strategic implications

This research employed a multi-faceted methodology that combined primary stakeholder interviews, technical literature review, and systematic analysis of product and regulatory developments to ensure a comprehensive and balanced perspective. Primary engagements included conversations with R&D leaders, clinical laboratory directors, procurement specialists, and commercial leaders across instrument and reagent providers. These interactions were structured to elicit insights into operational challenges, adoption drivers, and strategic responses to evolving policy and supply chain conditions.

Secondary research involved the review of peer-reviewed journals, conference proceedings, patent filings, and public regulatory documents to validate technical trends and to trace the evolution of key technologies. Additionally, catalogues of product specifications, vendor disclosures, and publicly available case studies were synthesized to map feature differentials, integration capabilities, and deployment contexts. The methodology emphasized triangulation across sources to reduce bias and to reconcile differing perspectives on technology maturity and clinical readiness.

Analytical frameworks included segmentation mapping, scenario planning for supply chain risk, and evaluation of commercial models based on pricing, service scope, and customer support structures. Throughout, quality assurance processes were applied to check factual accuracy and to ensure that conclusions are supported by multiple independent inputs. The result is a rigorous evidence-based assessment designed to inform strategic planning and operational decision-making.

A conclusive synthesis emphasizing adaptability, technical integration, and governance as the decisive factors for sustained success in the evolving genomics ecosystem

The concluding synthesis reiterates that genomics is at an inflection point where technological capability, commercial innovation, and regulatory stewardship intersect to define future winners and laggards. Organizations that align investments in interoperable platforms, resilient supply chains, and outcome-driven services will create durable competitive advantages. Moreover, proactive engagement with regulatory and data governance issues will accelerate the translation of laboratory advances into clinical and commercial impact.

Looking ahead, the ability to translate complex data streams into actionable decisions-whether for therapeutic development, diagnostic deployment, or agricultural improvement-will distinguish high-performing organizations. Strategic partnerships, flexible business models, and a relentless focus on customer outcomes will enable firms to capture emerging opportunities while mitigating operational risks. The key message is that adaptability, technical excellence, and trustworthiness are the principal currencies in a rapidly changing genomics ecosystem.

In closing, this analysis provides a structured foundation for leaders to prioritize investments, shape product roadmaps, and refine commercial approaches. By focusing on the levers that most strongly influence adoption and value realization, organizations can navigate uncertainty and position themselves for sustainable impact in research, clinical care, and broader applied genomics contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of nanopore long-read sequencing for comprehensive structural variant analysis in clinical diagnostics
  • 5.2. Integration of multi-omics data with AI algorithms to accelerate targeted drug discovery pipelines
  • 5.3. Scaling real-time pathogen surveillance through portable sequencing devices in global pandemic preparedness
  • 5.4. Expansion of direct-to-consumer genetic health testing and associated privacy and regulatory challenges
  • 5.5. Emergence of epigenetic biomarker panels for early cancer detection and precision oncology decision making
  • 5.6. Regulatory harmonization efforts for CRISPR gene editing therapies across major international markets
  • 5.7. Deployment of cloud-native genomic data platforms to streamline collaborative research and data sharing
  • 5.8. Utilization of single-cell multi-omics profiling to uncover cellular heterogeneity in complex diseases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genomics Market, by Product Type

  • 8.1. Microarrays
    • 8.1.1. Gene Expression Arrays
    • 8.1.2. SNP Genotyping Arrays
  • 8.2. PCR
    • 8.2.1. Digital PCR
    • 8.2.2. qPCR
  • 8.3. Reagents & Consumables
    • 8.3.1. Enzymes & Master Mixes
    • 8.3.2. Library Preparation Kits
    • 8.3.3. Probes & Primers
  • 8.4. Sequencing Services
    • 8.4.1. NGS Services
    • 8.4.2. Sanger Sequencing Services
  • 8.5. Sequencing Systems
    • 8.5.1. NGS Platforms
    • 8.5.2. Sanger Sequencers

9. Genomics Market, by Application

  • 9.1. Agriculture
    • 9.1.1. Animal Genomics
    • 9.1.2. Crop Genomics
  • 9.2. Diagnostics
    • 9.2.1. Cancer Genomics
    • 9.2.2. Genetic Testing
    • 9.2.3. Infectious Disease Testing
  • 9.3. Drug Discovery & Development
    • 9.3.1. Biomarker Discovery
    • 9.3.2. Target Identification
  • 9.4. Personalized Medicine
    • 9.4.1. Companion Diagnostics
    • 9.4.2. Precision Therapeutics

10. Genomics Market, by End User

  • 10.1. Academic & Government Institutes
  • 10.2. Commercial Research Organizations
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Genomics Market, by Technology

  • 11.1. Array Technology
    • 11.1.1. Microarray Gene Expression
    • 11.1.2. SNP Genotyping Arrays
  • 11.2. DNA Sequencing
    • 11.2.1. Next-Generation Sequencing
    • 11.2.2. Sanger Sequencing
  • 11.3. PCR Technology
    • 11.3.1. Digital PCR
    • 11.3.2. qPCR
  • 11.4. RNA Sequencing
    • 11.4.1. Bulk RNA Sequencing
    • 11.4.2. Single-Cell RNA Sequencing

12. Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. Danaher Corporation
    • 15.3.6. Agilent Technologies, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Bio-Rad Laboratories, Inc.
    • 15.3.10. Pacific Biosciences of California, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GENOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. GENOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENOMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENOMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 333. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 334. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 335. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 339. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 342. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 343. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 344. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 345. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 346. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2025-2032 (USD MILLION)

TABLE 347